Visualizing Health Policy: US Public’s Perspective on Prescription Drug Costs
US Public’s Opinion of Prescription Drug Costs Download VIEW JAMA INFOGRAPHIC…
View the Latest: Prescription Drugs
Filter
-
-
State Medicaid Management of Prescription Drugs for HIV Treatment and Prevention
Issue BriefThis data note, primarily based on a survey of state Medicaid pharmacies, reviews cost-containment policies and protections as they relate to antiretrovirals for treatment and prevention of HIV.
-
KFF Health Tracking Poll – May 2021: Prescription Drug Prices Top Public’s Health Care Priorities
FeatureThe latest KFF Health Tracking Poll explores the public's views on the U.S. role in distributing COVID vaccines to other countries, health care priorities for Congress, prescription drug regulations and price negotiations, and affordability changes in the COVID-19 relief bill.
-
Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2021
Issue BriefThe Medicare Part D program provides an outpatient prescription drug benefit to older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone drug plans and Medicare Advantage drug plans. This analysis provides the latest data about Part D enrollment, premiums, and cost sharing in 2021 and trends over time.
-
Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs, 2015-2019
Issue BriefPrescription drug spending in Medicaid and other health programs has returned to the national policy debate. This analysis examines Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for targeted policy action.
-
Public Opinion on Prescription Drugs and Their Prices
Poll FindingThis chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include Americans' opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices, including the Inflation Reduction Act.
-
Costs and Savings under Federal Policy Approaches to Address Medicaid Prescription Drug Spending
Issue BriefThis brief analyzes leading federal approaches to address Medicaid prescription drug spending, discusses (where available) a range of cost estimates for each policy, and assesses what drives those estimates or where there is uncertainty in them.
-
A Record 3,834 Medicare Advantage Plans Will be Available in 2022, Up 8 Percent From 2021, While the Number of Medicare Part D Stand-Alone Plans is Decreasing Mainly Due to Firm Consolidations
News ReleaseA record 3,834 Medicare Advantage plans will be available across the country as alternatives to traditional Medicare for 2022, a new KFF analysis finds. That’s an increase of 8 percent from 2021, and the largest number of plans available in more than a decade.
-
Summary of Costs and Impact of the Prescription Drug Provisions in the Build Back Better Act
News ReleaseAs the House-passed Build Back Better Act moves to the Senate, a new explainer from KFF summarizes the key prescription drug provisions within the broader budget reconciliation bill. These provisions would lower prescription drug costs paid by people with Medicare and private insurance and curb drug spending by the federal government and private payers.
-
How Build Back Better Would Affect Drug Costs
FeatureProvisions in the bill that would lower prescription drug costs and reduce federal drug spending would take effect over the next several years, starting in 2023.